rAAV with chemically modified capsid
The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.
1. An adeno-associated virus (AAV) vector particle comprising a ligand covalently linked to a primary amino group of a capsid polypeptide via a CSNH— bond,
wherein the ligand comprises an arylene or heteroarylene radical covalently bound to the ligand, wherein the ligand is a targeting ligand, and
wherein the ligand promotes infection of a cell of the eye.
2. The AAV particle of claim 1 , wherein the cell of the eye is a cell of the retina.
3. The AAV particle of claim 2 , wherein the cell of the retina is a photoreceptor or a retinal pigmented epithelium (RPE) cell.
4. The AAV particle of claim 1 , wherein the ligand comprises a mannose, galactose or N-acetylgalactosamine moiety.
5. The AAV particle of claim 1 , wherein the ligand comprises a bond or a spacer (X) between said ligand and said arylene or heteroarylene radical.
6. The AAV particle of claim 5 , wherein the spacer (X) represents:
a group
wherein n represents an integer from 3 to 20.
7. The AAV particle of claim 1 , wherein the ligand has the following formula (D):
8. The AAV particle of claim 1 , wherein the capsid polypeptide is a wild-type capsid polypeptide from a naturally-occurring AAV serotype.
9. The AAV particle of claim 1 , wherein the capsid polypeptide is a recombinant capsid polypeptide.
10. A pharmaceutical composition comprising the AAV particle of claim 1 and a pharmaceutically acceptable carrier or excipient.